5-Chloro-1,3-dimethyl-1H-pyrazole-4-carboxylic acid, 97.0%, 25g

3,4-Dihydro-2h-1,4-benzothiazine-1,1-dione, 97%, 1g

3'-Chloro-2,2,2,4'-tetrafluoroacetophenone, 97.0%, 250mg

Plan PLPHi S40x/0.65 phase contrast IOS infinity corrected objective

3,6-Bis(5-bromothiophen-2-yl)-2,5-dioctylpyrrolo[3,4-c]pyrrole-1,4(2H,5H)-dione, 95%, 250mg

2-Hydroxyanthracene-9,10-dione, 95.0%, 25g

2,2,2-Trichloro-1-(4-nitro-1h-pyrrol-2-yl)ethan-1-one, 95+%, 5g

2-Amino-2-methyl-propionitrile hydrochloride, 95.0%, 5g

Morpholine-2-carboxamide, 97%, 1g

3-Chloro-5-(difluoromethoxy)aniline, 98%, 250mg

5,10,15,20-Tetra(pyridin-3-yl)porphyrin, 97%, 1g

1-Bromo-2,3,4,5,6-pentamethylbenzene, 98.0%, 25g

2-(Furan-2-yl)-7-(3-(4-methoxyphenyl)propyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, 95.0%, 25mg